

Cara A Timpani

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/9368066/publications.pdf>

Version: 2024-02-01

25
papers

690
citations

566801

15
h-index

610482

24
g-index

27
all docs

27
docs citations

27
times ranked

1061
citing authors

#	ARTICLE	IF	CITATIONS
1	Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 42-54.	2.9	3
2	Micro (mRNA) molecules could pack a big punch in the fight against neuromuscular disease. <i>Journal of Physiology</i> , 2021, 599, 5-6.	1.3	0
3	Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy. <i>Redox Biology</i> , 2021, 38, 101803.	3.9	25
4	Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 117.	1.2	41
5	Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia. <i>Pharmaceuticals</i> , 2021, 14, 478.	1.7	7
6	Adenylosuccinic acid: a novel inducer of the cytoprotectant Nrf2 with efficacy in Duchenne muscular dystrophy. <i>Current Medical Research and Opinion</i> , 2021, 37, 465-467.	0.9	4
7	Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 15.	1.7	28
8	Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?. <i>Pharmaceuticals</i> , 2020, 13, 306.	1.7	52
9	Sodium nitrate co-supplementation does not exacerbate low dose metronomic doxorubicin-induced cachexia in healthy mice. <i>Scientific Reports</i> , 2020, 10, 15044.	1.6	5
10	Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?. <i>Antioxidants</i> , 2020, 9, 1268.	2.2	10
11	The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle. <i>Cells</i> , 2020, 9, 2657.	1.8	39
12	The Paradoxical Effect of PARP Inhibitor BGP-15 on Irinotecan-Induced Cachexia and Skeletal Muscle Dysfunction. <i>Cancers</i> , 2020, 12, 3810.	1.7	7
13	Testosterone suppression does not exacerbate disuse atrophy and impairs muscle recovery that is not rescued by high protein. <i>Journal of Applied Physiology</i> , 2020, 129, 5-16.	1.2	8
14	Exercise May Ameliorate the Detrimental Side Effects of High Vitamin D Supplementation on Muscle Function in Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1092-1106.	3.1	11
15	Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy. <i>Scientific Reports</i> , 2020, 10, 1125.	1.6	24
16	The Effect of Vitamin D Supplementation on Skeletal Muscle in the mdx Mouse Model of Duchenne Muscular Dystrophy. <i>Sports</i> , 2019, 7, 96.	0.7	6
17	Chemotherapeutic agents induce mitochondrial superoxide production and toxicity but do not alter respiration in skeletal muscle in vitro. <i>Mitochondrion</i> , 2018, 42, 33-49.	1.6	17
18	Oxaliplatin-induced enteric neuronal loss and intestinal dysfunction is prevented by co-treatment with BGP-15. <i>British Journal of Pharmacology</i> , 2018, 175, 656-677.	2.7	34

#	ARTICLE	IF	CITATIONS
19	Attempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle. <i>Neurotherapeutics</i> , 2017, 14, 429-446.	2.1	28
20	Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 100.	1.2	18
21	BGP-15 Protects against Oxaliplatin-Induced Skeletal Myopathy and Mitochondrial Reactive Oxygen Species Production in Mice. <i>Frontiers in Pharmacology</i> , 2017, 8, 137.	1.6	30
22	Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 673-683.	1.1	61
23	Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology. <i>Medical Hypotheses</i> , 2015, 85, 1021-1033.	0.8	106
24	Metabogenic and Nutraceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy. <i>Nutrients</i> , 2015, 7, 9734-9767.	1.7	20
25	Defects in Mitochondrial ATP Synthesis in Dystrophin-Deficient Mdx Skeletal Muscles May Be Caused by Complex I Insufficiency. <i>PLoS ONE</i> , 2014, 9, e115763.	1.1	103